- slider1.jpg
- slider1.jpg
TREATING DEADLY INFLAMMATION
CytoSorb® is a unique blood purification therapy to control deadly inflammation in life threatening illnesses in the ICU and cardiac surgery. The product is currently approved in the European Union and distributed in 55 countries around the world.
THE POWER OF THE BEAD
Powered by massive surface area, our purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
INFORMATION FOR INVESTORS
CytoSorbents is a leader in critical care immunotherapy. The company is committed to serving the best interests of our patients and their families, our customers, our employees, and our shareholders.
Recent News
- CytoSorbents Reports First Quarter 2019 Financial Results and Provides Second Quarter 2019 Guidance
- CytoSorbents to Report Q1 2019 Operating and Financial Results
- CytoSorbents Highlights the 6th International CytoSorb Users' Meeting and Recent Activities at the 2019 ISICEM and EuroELSO Conferences
- CytoSorbents to Present at the H.C. Wainwright Global Life Sciences Conference 2019 London
- Israel Approves CytoSorb Registration, CytoSorbents Announces Gad Medical as Distributor
Videos to Watch On The Street - "Cytosorbents CEO on How to Avoid the Flu
and Cytokine Storms" click here
- slider1.jpg
